Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
AbstractThe proposed study examined the characterization and stability of solid-state amorphous imatinib mesylate (IM) after 15 months under controlled relative humidity (60 ± 5%) and temperature (25 ± 2 °C) conditions. After 2 weeks, and 1, 3, 6, and 15 months, the samples were characterized using differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), X-ray powder diffractometry (XRPD), attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) and scanning electron microscopy (SEM). Additionally, the amorphous form of imatinib mesylate was obtained via supercooling of the melt in a DSC apparatus, and aged at various temperatures (3, 15, 25 and 30 °C) and time periods (1–16 h). Glass transition and enthalpy relaxation were used to calculate molecular-relaxation-time parameters. The Kohlrausch–Williams–Watts (KWW) equation was applied to fit the experimental enthalpy-relaxation data. The mean molecular-relaxation-time constant (τ) increased with decreasing ageing temperature. The results showed a high stability of amorphous imatinib mesylate adequate to enable its use in solid dosage form. View Full-Text
Share & Cite This Article
Karolewicz, B.; Górniak, A.; Marciniak, D.M.; Mucha, I. Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate. Pharmaceutics 2019, 11, 304.
Karolewicz B, Górniak A, Marciniak DM, Mucha I. Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate. Pharmaceutics. 2019; 11(7):304.Chicago/Turabian Style
Karolewicz, Bożena; Górniak, Agata; Marciniak, Dominik M.; Mucha, Igor. 2019. "Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate." Pharmaceutics 11, no. 7: 304.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.